everyone deserves to see the world clearly
through healthy eyes
Our Mission
At Dopavision, we’re bringing a new perspective to the world of eye care. By combining selective ocular light stimulation with accessible consumer electronics, we non-invasively activate the eye’s innate signaling pathways. Our goal is to address a significant global public health issue and empower as many people as possible to lead a healthier, brighter future.
MyopiaX® Clinical Trial
MyopiaX® is our transformative approach that aims to slow the progression of myopia (nearsightedness) in children and adolescents. Administering patented, first-in-class selective ocular light stimulation targeting the eye’s blind spot, MyopiaX® non-invasively engages the innate mechanisms regulating eye growth. By using consumer electronics, MyopiaX® aims to offer an interactive, child-friendly approach, designed to integrate seamlessly into daily routines.
MyopiaX® was investigated in a multicenter, randomized controlled clinical trial (NCT04967287) to evaluate its safety, tolerability, and signals of clinical effect on myopia progression in children. The completion of the MyopiaX-1 proof-of-concept trial marks a crucial step towards our mission of providing a safe, non-invasive therapeutic alternative to slow the progression of myopia.
The Global Myopia Crisis
Our Product
Our lead product is MyopiaX®, a breakthrough technology targeted at children and young adolescents. It has the potential to become the first digital therapy to control childhood myopia, leveraging our patented, light-based technology that stimulates specific photosensitive cells in the retina.
MyopiaX® is designed to achieve a medical effect while children play exciting games or use educational digital content. It runs on standard digital devices and is easy to use for children under minimal supervision of their parents. A clinical investigation evaluating the efficacy of MyopiaX® is currently underway.
Our Partners
Dopavision is funded as part of the BMBF’s Industry-in-Clinic Platform Program (FKZ: 13GW0625)